Shu-Wei Chen
Papers
2
Total Citations
9
H-Index
2
About
Shu-Wei Chen is a leading surgical oncologist and clinical researcher whose work centers on de-escalation strategies for HPV-associated oropharyngeal cancer (OPC). His major contributions lie in pioneering the integration of neoadjuvant immunochemotherapy—specifically the anti-PD-1 agent sintilimab combined with platinum-doublet chemotherapy—followed by transoral robotic surgery (TORS) for resectable HPV-positive OPC. Chen’s landmark single-arm, phase II trial (2024) and its subsequent two-centre phase 2 expansion (2025) have demonstrated that this combined approach can achieve major pathological responses while potentially reducing the need for more toxic adjuvant treatments. These studies, already garnering early citations, are reshaping clinical thinking around organ preservation and treatment de-escalation in a patient population with favorable prognoses. Chen’s work is notable for its direct translational impact: by showing that neoadjuvant immunotherapy can be safely paired with minimally invasive surgery, he is helping to define a new standard for HPV+ OPC care. His research continues to influence ongoing trials and clinical guidelines, positioning him as a key voice in the evolution of head and neck cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2